JP2022514693A5 - - Google Patents

Info

Publication number
JP2022514693A5
JP2022514693A5 JP2021536072A JP2021536072A JP2022514693A5 JP 2022514693 A5 JP2022514693 A5 JP 2022514693A5 JP 2021536072 A JP2021536072 A JP 2021536072A JP 2021536072 A JP2021536072 A JP 2021536072A JP 2022514693 A5 JP2022514693 A5 JP 2022514693A5
Authority
JP
Japan
Prior art keywords
antibody
cdr2
cdr1
cdr3
muc18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514693A (ja
JP7575102B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067387 external-priority patent/WO2020132190A1/en
Publication of JP2022514693A publication Critical patent/JP2022514693A/ja
Publication of JP2022514693A5 publication Critical patent/JP2022514693A5/ja
Application granted granted Critical
Publication of JP7575102B2 publication Critical patent/JP7575102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536072A 2018-12-21 2019-12-19 Muc18に特異的な抗体 Active JP7575102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018122567 2018-12-21
CNPCT/CN2018/122567 2018-12-21
PCT/US2019/067387 WO2020132190A1 (en) 2018-12-21 2019-12-19 Antibodies specific to muc18

Publications (3)

Publication Number Publication Date
JP2022514693A JP2022514693A (ja) 2022-02-14
JP2022514693A5 true JP2022514693A5 (https=) 2022-12-16
JP7575102B2 JP7575102B2 (ja) 2024-10-29

Family

ID=71101893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536072A Active JP7575102B2 (ja) 2018-12-21 2019-12-19 Muc18に特異的な抗体

Country Status (7)

Country Link
US (1) US12371509B2 (https=)
EP (1) EP3898698B1 (https=)
JP (1) JP7575102B2 (https=)
CN (2) CN117447599A (https=)
AU (1) AU2019401647A1 (https=)
TW (1) TWI851634B (https=)
WO (1) WO2020132190A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7578289B2 (ja) 2018-12-21 2024-11-06 マルチチュード インコーポレーテッド Muc18に特異的な抗体
US20240316099A1 (en) * 2020-09-30 2024-09-26 Baylor College Of Medicine Cytotoxic and costimulatory chimeric antigen receptors
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
KR20250080903A (ko) * 2022-10-19 2025-06-05 멀티튜드 테라퓨틱스 인코퍼레이티드 항체-약물 접합체, 이의 제조 방법 및 용도
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4716750A1 (en) 2023-05-23 2026-04-01 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117069848B (zh) * 2023-08-02 2025-02-28 武汉爱博泰克生物科技有限公司 抗人cd146兔单克隆抗体及其应用
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
CN120463814A (zh) * 2024-02-07 2025-08-12 北京艺妙神州医药科技有限公司 靶向muc18的嵌合抗原受体及其用途
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
CA2489769A1 (en) 1989-03-21 1990-10-04 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
PT695169E (pt) 1993-04-22 2003-04-30 Skyepharma Inc Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
DE69535669T2 (de) 1994-05-09 2008-12-04 Oxford Biomedica (Uk) Ltd. Retrovirale vektoren mit verminderter rekombinationsrate
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US6824995B1 (en) * 1998-03-03 2004-11-30 Emory University Diagnostic for metastatic prostate cancer
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
JP2005516965A (ja) 2001-12-28 2005-06-09 アブジェニックス・インコーポレーテッド 抗muc18抗体を使用する方法
HUE026846T2 (en) 2007-12-18 2016-08-29 Bioalliance Cv Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
CN101245101B (zh) * 2008-01-31 2013-10-16 中国科学院生物物理研究所 抗人cd146的单克隆抗体,包含其的组合物,检测可溶性cd146的方法
WO2010145895A1 (en) * 2009-05-14 2010-12-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
ES2686692T3 (es) 2013-09-24 2018-10-19 Oncoinvent As Anticuerpo monoclonal anti CD146
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
CN104650231A (zh) 2015-02-13 2015-05-27 南京任诺药业有限公司 一种具备高效中和活性的人源化抗人cd146单克隆抗体
EP3350226A2 (en) * 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
US20190192573A1 (en) * 2016-08-19 2019-06-27 Oncoinvent As Anti-osteosarcoma car-t derived from the antibody oi-3
WO2018220467A1 (en) * 2017-05-30 2018-12-06 Foroogh Nejatollahi Anti-muc18 human immunotoxin and applications thereof
CN108129567B (zh) * 2018-01-09 2019-02-26 南京任诺药业有限公司 一种具备高效中和活性的人源化抗人cd146单克隆抗体
JP7578289B2 (ja) 2018-12-21 2024-11-06 マルチチュード インコーポレーテッド Muc18に特異的な抗体

Similar Documents

Publication Publication Date Title
JP2022514693A5 (https=)
JP2022523710A5 (https=)
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
KR102952460B1 (ko) Cd3 항체 및 그의 약제학적 용도
JP2022541435A5 (https=)
JP7202185B2 (ja) 抗cd3抗体及び該抗体を含む分子
JP2020510422A5 (https=)
JP2019500892A5 (https=)
JP2020508655A5 (https=)
JP2021508469A5 (https=)
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CN110121510A (zh) 程序性细胞死亡(pd-1)的单结构域抗体
WO2018108106A1 (zh) 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞
JP2019525738A5 (https=)
JP2019524693A5 (https=)
IL312224B1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2019500891A5 (https=)
KR20170102167A (ko) 항-pd-l1 항체
FI3334765T3 (fi) Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2022542559A5 (https=)
JP2018526981A5 (https=)
JP2011526785A5 (https=)
IL273196B1 (en) Claudin 6 antibodies and methods of cancer treatment
JP2021531825A5 (https=)
JP2024001073A5 (https=)